Invokana (Canagliflozin) as a dual inhibitor of acetylcholinesterase and sodium glucose co-transporter 2: Advancement in Alzheimer's disease-diabetes type 2 linkage via an enzoinformatics study

CNS and Neurological Disorders - Drug Targets

Volumn 13, Issue 3, 2014, Pages 447-451

  Rizvi, Syed M D ^a   Shakil, Shahnawaz ^b   Biswas, Deboshree ^a   Shakil, Shazi ^a   Shaikh, Sibhghatulla ^a   Bagga, Paramdeep ^a   Kamal, Mohammad A ^c  

^a INTEGRAL UNIVERSITY   (India)

^b CARDINAL HEALTH   (United States)

^c KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Acetylcholinesterase; Canagliflozin; Docking; Invokana; Sodium glucose co transporter

Indexed keywords

ACETYLCHOLINESTERASE; CANAGLIFLOZIN; GLUCOSE; INSULIN; SODIUM GLUCOSE COTRANSPORTER 2; CHOLINESTERASE INHIBITOR; GLUCOSIDE; THIOPHENE DERIVATIVE;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; ARTICLE; CHEMICAL ANALYSIS; CHEMICAL STRUCTURE; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG ACTIVITY; ENZYME ACTIVITY; ENZYME SUBSTRATE COMPLEX; EXPERIMENTAL MODEL; HUMAN; MOLECULAR DOCKING; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; COMPLICATION; COMPUTER SIMULATION; DIABETES MELLITUS, TYPE 2; METABOLISM; PROTEIN DATABASE; STATISTICS AND NUMERICAL DATA;

ALZHEIMER DISEASE; ANIMALS; CHOLINESTERASE INHIBITORS; COMPUTER SIMULATION; DATABASES, PROTEIN; DIABETES MELLITUS, TYPE 2; GLUCOSIDES; HUMANS; MODELS, MOLECULAR; SODIUM-GLUCOSE TRANSPORTER 2; THIOPHENES;

EID: 84904503557     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/18715273113126660160     Document Type: Article

References (51)

1. Lin L. Commonality between Diabetes and Alzheimer's Disease and a new strategy for the therapy. Clin Med Path 2008; 1: 83-91.
2. Suzanne MM, Jack RW. Alzheimer's Disease Is Type 3 Diabetes- Evidence Reviewed. J Diabetes Sci Tech 2008; 2(6): 1101-13.
3. Pasquier F, Boulogne A, Leys D, Fontaine P. Diabetes mellitus and dementia. Diabetes Metab 2006; 32(5): 403-14.
4. Haan MN, Wallace R. Can dementia be prevented? Brain aging in a population-based context. Annu Rev Public Health 2004; 25: 1-24.
5. Launer LJ. Diabetes and brain aging: epidemiologic evidence. Curr Diab Rep 2005; 5(1): 59-63.
6. Luchsinger JA, Mayeux R. Cardiovascular risk factors and Alzheimer's disease. Curr Atheroscler Rep 2004; 6(4): 261-6.
7. Luchsinger JA, Reitz C, Patel B, et al. Relation of diabetes to mild cognitive impairment. Arch Neurol 2007; 64(4): 570-5.
8. Whitmer RA. Type 2 diabetes and risk of cognitive impairment and dementia. Curr Neurol Neurosci Rep 2007; 7(5): 373-80.
9. Li L, Holscher C. Common pathological processes in Alzheimer disease and type 2 diabetes: A review. Brain Res Rev 2007; 56: 384-402.
10. Ristow M. Neurodegenerative disorders associated with diabetes mellitus. J Mol Med 2004; 82: 510-29.
11. Haan MN. Therapy Insight: type 2 diabetes mellitus and the risk of lateonset Alzheimer's disease. Nat Clin Prac Neurol 2006; 2: 159-66.
12. Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multitasking kinase. J Cell Sci 2003; 116: 1175-86.
13. Qiu WQ, Folstein MF. Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis. Neurobiol Aging 2006; 27: 190-8.
14. Kroner Z. The Relationship between Alzheimer's disease and Diabetes: Type 3 Diabetes? Alternat Med Rev 2009; 14(4): 373-9.
15. Kyriakis JM, Hausman RE, Peterson SW. Insulin stimulates choline acetyltransferase activity in cultured embryonic chicken retina neurons. Proc Natl Acad Sci USA 1987; 84(21): 7463-7.
16. Brass BJ, Nonner D, Barrett JN. Differential effects of insulin on choline acetyltransferase and glutamic acid decarboxylase activities in neuron-rich striatal cultures. J Neurochem 1992; 59(2): 415-24.
17. Rivera EJ, Goldin A, Fulmer N, et al. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J Alzheimers Dis 2005; 8: 247-68.
18. Kawser A, Emily AL, Stephen AM, et al. Diabetes mellitus and Alzheimer's disease: shared pathology and treatment? Br J Clin Pharmacol 2011; 71(3): 365-76.
19. Theresa RB, Forny-Germano L, Sathler LB, et al. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associated Aβ oligomers. J Clin Invest 2012; 122(4): 1339-53.
20. Steen E, Terry BM, Rivera EJ, et al. Impaired insulin and insulinlike growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes? J Alzheimers Dis 2005; 7(1): 63-80.
21. Duelli R, Schröck H, Kuschinsky W, Hoyer S. Intracerebroventricular injection of streptozotocin induces discrete local changes in cerebral glucose utilization in rats. Int J Dev Neurosci 1994; 12(8): 737-43.
22. Lannert H, Hoyer S. Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats. Behav Neurosci 1998; 112(5): 1199-208.
23. Plaschke K, Hoyer S. Action of the diabetogenic drug streptozotocin on glycolytic and glycogenolytic metabolism in adult rat brain cortex and hippocampus. Int J Dev Neurosci 1993; 11(4): 477-83.
24. Jabbour SA, Goldstein BJ. Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes. Int J Clin Pract 2008; 62: 1279-84.
25. Rajesh R, Naren P, Sudha V, et al. Sodium Glucose Co transporter 2 (SGLT2) Inhibitors: A New Sword for the Treatment of Type 2 Diabetes Mellitus. Int J Phar Sci Res 2010; 1(2): 139-47.
26. Kanai Y, Lee WS, You G, Brown D, Hediger MA. The human kidney low affinity Na/glucose cotransporter SGLT2: delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Investig 1994; 93: 397-404.
27. Edward CC, Robert RH. SGLT2 inhibition - a novel strategy for diabetes treatment. Nat Rev Drug Discov 2010; 1-9.
28. Bakris GL, Fonseca VA, Sharma K, Wright EM. Renal sodiumglucose transport: role in diabetes and potential clinical implications. Kidney Int 2009; 75: 1272-7.
29. Medical News Today. Invokana (canaglifozin) For Type 2 Diabetes Approved By FDA. 31 Mar 2013.
30. Block JH, Beale JM. Textbook of Organic Medicinal and Pharmaceutical Chemistry II. In: Cholinergic Drug and Related Agents. Cocolas GH, Cuter SJ. United state, Lippin Williams & Wilkins 2004.
31. Orhan I, Sener B, Choudhary MI, Khalid, A. Acetylcholinesterase and butyrylcholinesterase inhibitory activity of some Turkish medicinal plants. J Ethnopharmacol 2004; 91: 57-60.
32. Buncharoen W, Saenphet S, Saenphet K. Acetylcholinesterase Inhibitory Effect of Pseuderanthemum palatiferum in Albino Rats. Trends Res Sci Tech 2010; 2(1): 13-8.
33. Ghosh R. Current Status: Alzheimer's Disease. Kathmandu Uni Med J 2003; 1: 205-21.
34. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes Mellitus and risk of Alzheimer's Disease and decline in cognitive function. Arch Neurol 2004; 61(5): 661-6.
35. Peila R, Rodriguez BL, Launer LJ. Type 2 Diabetes, APOE gene and the risk for dementia and related pathologies. Diabetes 2002; 51(4): 1256-62.
36. Rahmoune H, Thompson PW, Ward JM, et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 2005, 54: 3427-34.
37. Rossetti L, Papachristou D, Shulman G, Smith D, Defronzo R. Insulin resistance in partially pancreatectomized rats- reversal with phlorizin therapy. Diabetologia 1986; 29: A587-8.
38. Han S, Hagan DL, Taylor JR, et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 2008; 57: 1723-9.
39. Katsuno K, Fujimori Y, Takemura Y, et al. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2): validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther 2007; 320: 323-30.
40. Komoroski B, Vachharajani N, Boulton D, et al. Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects. Clin Pharmacol Ther 2009; 85: 520-6.
41. Fujimori Y, Katsuno K, Nakashima I, et al. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther 2008; 327: 268-76.
42. Faham S, Watanabe A, Besserer GM, et al. The crystal structure of a sodium galactose transporter reveals mechanistic insights into Na+/sugar symport. Science 2008; 321: 810-4.
43. Díez-Sampedro A, Barcelona S. Sugar binding residue affects apparent Na affinity and transport stoichiometry in mouse sodium/glucose cotransporter type 3B. J Biol Chem 2011; 286(10): 7975-82.
44. Díez-Sampedro A, Wright EM, Hirayama BA. Residue 457 controls sugar binding and transport in the Na+/glucose cotransporter. J Biol Chem 2001; 276: 49188-94.
45. Liu T, Krofchick D, Silverman M. Effects on conformational states of the rabbit sodium/glucose cotransporter through modulation of polarity and charge at glutamine 457. Biophys J 2009; 96: 748-60.
46. Wright EM, Turk E, Martin MG. Molecular basis for glucosegalactose malabsorption. Cell Biochem Biophys 2002; 36: 115-21.
47. Lam JT, Martín MG, Turk E, et al. Missense mutations in SGLT1 cause glucose-galactose malabsorption by trafficking defects. Biochim Biophys Acta 1999; 1453: 297-303.
48. Silman I, Sussman JL. Acetylcholinesterase: 'classical' and 'nonclassical' functions and pharmacology. Curr Opin Pharmacol 2005; 5(3): 293-302.
49. Silman I, Sussman JL. Acetylcholinesterase: how is structure related to function? Chem Biol Interact 2008; 25: 3-10.
50. Sussman JL, Harel M, Frolow F, et al. Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein. Science 1991; 253(5022): 872-9.
51. Shakil S, Khan AU. Interaction of 2009 CTX-M variants with drugs and inhibitors: a molecular modelling and docking study. J Proteom Bioinform 2010; 3: 130-4.